These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 3136630

  • 21. Flecainide acetate in the treatment of tachycardias associated with Mahaim fibres.
    Lau CP, Davies DW, Mehta D, Ward DW, Camm AJ.
    Eur Heart J; 1987 Aug; 8(8):832-9. PubMed ID: 3117552
    [Abstract] [Full Text] [Related]

  • 22. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group.
    Pritchett EL, DaTorre SD, Platt ML, McCarville SE, Hougham AJ.
    J Am Coll Cardiol; 1991 Feb; 17(2):297-303. PubMed ID: 1899432
    [Abstract] [Full Text] [Related]

  • 23. [Electrophysiological effects and clinical efficacy of flecainide in childhood patients with supraventricular reciprocating paroxysmal tachycardia].
    Musto B, D'Onofrio A, Cavallaro C, Musto A, Della Gatta O, Marsico F.
    G Ital Cardiol; 1987 May; 17(5):444-9. PubMed ID: 3115857
    [Abstract] [Full Text] [Related]

  • 24. Neurohumoral and hemodynamic mechanisms of diuresis during atrioventricular nodal reentrant tachycardia.
    Abe H, Nagatomo T, Kobayashi H, Miura Y, Araki M, Kuroiwa A, Nakashima Y.
    Pacing Clin Electrophysiol; 1997 Nov; 20(11):2783-8. PubMed ID: 9392809
    [Abstract] [Full Text] [Related]

  • 25. Comparison of the electrophysiologic effects of oral sustained-release and intravenous verapamil in patients with paroxysmal supraventricular tachycardia.
    Lai WT, Voon WC, Yen HW, Chang JS, Sheu SH, Hwang YS, Chiu HF.
    Am J Cardiol; 1993 Feb 15; 71(5):405-8. PubMed ID: 8430627
    [Abstract] [Full Text] [Related]

  • 26. [Terminating supraventricular tachycardia with adenosine--comparing the effectiveness of 12 mg and 18 mg].
    Weismüller P, Kattenbeck K, Heinroth KM, Ranke C, Trappe HJ.
    Dtsch Med Wochenschr; 2000 Aug 18; 125(33):961-9. PubMed ID: 10994404
    [Abstract] [Full Text] [Related]

  • 27. Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients.
    Frandsen F, Pless P, Mickley H, Møller M.
    Acta Cardiol; 1990 Aug 18; 45(5):351-7. PubMed ID: 1704167
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds.
    Hellestrand KJ, Nathan AW, Bexton RS, Camm AJ.
    Am J Cardiol; 1984 Feb 27; 53(5):30B-38B. PubMed ID: 6695817
    [Abstract] [Full Text] [Related]

  • 30. Long-term follow-up of patients with inducible supraventricular tachycardia treated with flecainide or propafenone: therapy guided by transesophageal electropharmacologic testing.
    Furlanello F, Guarnerio M, Inama G, Vergara G, Del Greco M, Bertoldi A, Dallago M.
    Am J Cardiol; 1992 Aug 20; 70(5):19A-25A. PubMed ID: 1509994
    [Abstract] [Full Text] [Related]

  • 31. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group.
    Sung RJ, Tan HL, Karagounis L, Hanyok JJ, Falk R, Platia E, Das G, Hardy SA.
    Am Heart J; 1995 Apr 20; 129(4):739-48. PubMed ID: 7900626
    [Abstract] [Full Text] [Related]

  • 32. Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias.
    Sahar DI, Reiffel JA, Bigger JT, Squatrito A, Kidwell GA.
    Am Heart J; 1989 Mar 20; 117(3):562-8. PubMed ID: 2919535
    [Abstract] [Full Text] [Related]

  • 33. Long-term efficacy and safety of flecainide for supraventricular tachycardia.
    Neuss H, Schlepper M.
    Am J Cardiol; 1988 Aug 25; 62(6):56D-61D. PubMed ID: 3136637
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Flecainide for supraventricular tachycardia in children.
    Zeigler V, Gillette PC, Hammill B, Ross BA, Ewing L.
    Am J Cardiol; 1988 Aug 25; 62(6):41D-43D. PubMed ID: 3136635
    [Abstract] [Full Text] [Related]

  • 36. Clinical and electrophysiologic effects of magnesium sulfate on paroxysmal supraventricular tachycardia and comparison with adenosine triphosphate.
    Viskin S, Belhassen B, Sheps D, Laniado S.
    Am J Cardiol; 1992 Oct 01; 70(9):879-85. PubMed ID: 1529941
    [Abstract] [Full Text] [Related]

  • 37. Long-term antitachycardia pacing experience for supraventricular tachycardia.
    den Dulk K, Brugada P, Smeets JL, Wellens HJ.
    Pacing Clin Electrophysiol; 1990 Aug 01; 13(8):1020-30. PubMed ID: 1697949
    [Abstract] [Full Text] [Related]

  • 38. Effects of almokalant, a class III antiarrhythmic agent, on supraventricular, reentrant tachycardias. Almokalant Paroxysmal Supraventricular Tachycardia Study Group.
    Darpö B, Edvardsson N.
    Cardiovasc Drugs Ther; 1997 Jul 01; 11(3):499-508. PubMed ID: 9310280
    [Abstract] [Full Text] [Related]

  • 39. Surgical therapy for patients with supraventricular tachycardia.
    Ferguson TB, Cox JL.
    Cardiol Clin; 1990 Aug 01; 8(3):535-55. PubMed ID: 2205389
    [Abstract] [Full Text] [Related]

  • 40. Electrophysiological features differentiating the atypical atrioventricular node-dependent long RP supraventricular tachycardias.
    Ho RT, Frisch DR, Pavri BB, Levi SA, Greenspon AJ.
    Circ Arrhythm Electrophysiol; 2013 Jun 01; 6(3):597-605. PubMed ID: 23629734
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.